Research in the Glotzer Lab
Dr. Glotzer has dedicated her career to preventing strokes by exploring the link between atrial fibrillation (AF) and stroke. In 2003, she published a pioneering study connecting subclinical AF to increased risks of stroke and death. As the principal investigator of the TRENDS trial in 2009, she demonstrated that subclinical AF episodes exceeding 5.5 hours within 30 days double the risk of stroke. This research highlighted that asymptomatic AF detected by cardiac implanted electronic devices (CIEDs) elevates stroke risk. In 2017, Dr. Glotzer brought the ARTESIA trial to Hackensack University Medical Center (HUMC), and HUMC became a leading enrollment site. This double-blind study compared the efficacy of apixaban versus aspirin in patients with subclinical AF episodes lasting 6 minutes to 24 hours. Over an average follow-up of 3.5 years, results indicated that while apixaban reduced stroke or systemic embolism risk compared to aspirin, it also increased major bleeding.. Dr. Glotzer has since engaged in multiple sub-studies of ARTESIA and has been invited to present these findings globally.
With the advent of wearable technologies like smartwatches, AF detection has expanded beyond clinical settings. However, these devices often produce inconclusive rhythm strips. To address this, artificial intelligence (AI) has been employed to enhance diagnostic accuracy. Dr. Glotzer collaborates with companies that develop AI solutions to improve rhythm interpretation in wearable technology including smart watches.. In 2024, she brought the NIH-sponsored REACT-AF trial to HUMC; REACT will test a strategy of smartwatch-guided anticoagulation for stroke prevention in AF patients. Participants in the active arm receive AI-enhanced smartwatches to monitor AF burden, and will assess an intermittent anticoagulation approach.
In addition to AF research, Dr. Glotzer is studying new pacing strategies that can improve and preserve cardiac function. She introduced the Left vs. Left trial at HUMC in 2024. This NIH-sponsored study compares conduction system pacing to coronary sinus pacing in heart failure patients, aiming to determine which method yields better long-term outcomes.
Looking ahead, Dr. Glotzer aims to integrate AI solutions within the Hackensack Meridian Health network to enhance inpatient telemetry monitoring, striving for improved accuracy, cost savings, and improved patient outcomes.
Recent Publications
Brandes A, Stavrakis S, Freedman B, … Glotzer T, et al. Consumer-led screening for atrial fibrillation: frontier review of the AF-SCREEN International Collaboration. Circulation. 2022. PMID: 36343103.
Glotzer TV. Residual stroke risk in atrial fibrillation: Our patients must be our partners. Heart Rhythm O2. 2022. PMID: 36589912.
Andrade JG, Deyell MW, Macle L, … Glotzer TV, et al. Healthcare utilization and quality of life for atrial fibrillation burden: the CIRCA-DOSE study. Eur Heart J. 2023. PMID: 36459112.
Chung MK, Patton KK, Lau CP, … Glotzer TV, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023. PMID: 37283271
McIntyre W, Benz A, Healey J,….. Glotzer TV et al . Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial. Circulation. 2024. PMID: 39229707
Doehner W, Camm J, Glotzer TV et al. Atrial Fibrillation Burden in Clinical Practice, Research and Technology Development. A Clinical Consensus Statement of the ESC Council on Stroke and the European Heart Rhythm Association of the ESC Europace (2025). https://doi.org/10.1093/europace/euaf019
Johnson LS, Benz AP, Glotzer TV, Healey JS, et al. Artificial Intelligence for Analysis of Ambulatory Electrocardiography. Nature Medicine, In press 2025
Svennberg E, Freedman B, Glotzer TV et al. Treatment of Recent-Onset Atrial
Fibrillation: Opportunities and Outcomes. A Frontier Review from the AF-SCREEN International Collaboration. Under review 2025